Who it fits: Patients focused on metabolic optimization and longevity who also want physical recovery support
In 2022, SAR441255 (GLP-1/GIP/glucagon receptor triagonist) was administered to obese, diabetic primates and healthy lean to overweight humans without diabetes
In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
Furthermore, a broad knowledge of incretin physiology, pharmacology, and pathophysiology will be necessary to design highly effective and potent incretin-based therapies for different diseases
While the drug does the heavy lifting, a healthy microbiome plays a silent role in how your body processes sugar
To support hydration and nutrient intake during treatment, GLP-1 Daily Support supplement may be worth exploring